The clinical development of histone deacetylase inhibitors as targeted anticancer drugs

Bibliography

• Handel AE, Ebers GC, Ramagopalan SV. Epigenetics: molecular mechanisms and implications for disease. Trends Mol Med 2009;16(1):7-16
   PubMed Web of Science ®Google Scholar
• Ho DH, Burggren WW. Epigenetics and transgenerational transfer: a physiological perspective. J Exp Biol 2010;213(Pt 1):3-16
   PubMed Web of Science ®Google Scholar
• Yang XJ, Seto E. Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression. Curr Opin Genet Dev 2003;13(2):143-53
   PubMed Web of Science ®Google Scholar
• Shahbazian MD, Grunstein M. Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem 2007;76:75-100
   PubMed Web of Science ®Google Scholar
• Jenuwein T, Allis CD. Translating the histone code. Science 2001;293(5532):1074-80
   PubMed Web of Science ®Google Scholar
• Marks PA, Xu WS. Histone deacetylase inhibitors: potential in cancer therapy. J cell biochem 2009;107(4):600-8
   PubMed Web of Science ®Google Scholar
• Choudhary C, Kumar C, Gnad F, Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009;325(5942):834-40
   PubMed Web of Science ®Google Scholar
• Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009;10(1):32-42
   PubMed Web of Science ®Google Scholar
• Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004;338(1):17-31
   PubMed Web of Science ®Google Scholar
• Lagger G, O'Carroll D, Rembold M, Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 2002;21(11):2672-81
   PubMed Web of Science ®Google Scholar
• Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007;5(10):981-9
   PubMed Web of Science ®Google Scholar
• Montgomery RL, Davis CA, Potthoff MJ, Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev 2007;21(14):1790-802
   PubMed Web of Science ®Google Scholar
• Marchion DC, Bicaku E, Turner JG, HDAC2 regulates chromatin plasticity and enhances DNA vulnerability. Mol Cancer Ther 2009;8(4):794-801
   PubMed Web of Science ®Google Scholar
• Bhaskara S, Chyla BJ, Amann JM, Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol Cell 2008;30(1):61-72
   PubMed Web of Science ®Google Scholar
• Chen B, Cepko CL. HDAC4 regulates neuronal survival in normal and diseased retinas. Science 2009;323(5911):256-9
   PubMed Web of Science ®Google Scholar
• Williams AH, Valdez G, Moresi V, MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science 2009;326(5959):1549-54
   PubMed Web of Science ®Google Scholar
• Chang S, Young BD, Li S, Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 2006;126(2):321-34
   PubMed Web of Science ®Google Scholar
• Haggarty SJ, Koeller KM, Wong JC, Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 2003;100(8):4389-94
   PubMed Web of Science ®Google Scholar
• Parmigiani RB, Xu WS, Venta-Perez G, HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc Natl Acad Sci USA 2008;105(28):9633-8
   PubMed Web of Science ®Google Scholar
• Zhang X, Yuan Z, Zhang Y, HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell 2007;27(2):197-213
   PubMed Web of Science ®Google Scholar
• Kovacs JJ, Murphy PJ, Gaillard S, HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005;18(5):601-7
   PubMed Web of Science ®Google Scholar
• Kawaguchi Y, Kovacs JJ, McLaurin A, The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003;115(6):727-38
   PubMed Web of Science ®Google Scholar
• Boyault C, Gilquin B, Zhang Y, HDAC6-p97/VCP controlled polyubiquitin chain turnover. EMBO J 2006;25(14):3357-66
   PubMed Web of Science ®Google Scholar
• Villagra A, Cheng F, Wang HW, The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol 2009;10(1):92-100
   PubMed Web of Science ®Google Scholar
• Van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 1996;5(4-5):245-53
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Mitsiades NS, McMullan CJ, Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 2004;101(2):540-5
   PubMed Web of Science ®Google Scholar
• Gray SG, Qian CN, Furge K, Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. Int J Oncol 2004;24(4):773-95
   PubMed Web of Science ®Google Scholar
• Peart MJ, Smyth GK, van Laar RK, Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005;102(10):3697-702
   PubMed Web of Science ®Google Scholar
• Dokmanovic M, Perez G, Xu W, Histone deacetylase inhibitors selectively suppress expression of HDAC7. Mol Cancer Ther 2007;6(9):2525-34
   PubMed Web of Science ®Google Scholar
• Sengupta N, Seto E. Regulation of histone deacetylase activities. J Cell Biochem 2004;93(1):57-67
   PubMed Web of Science ®Google Scholar
• Finnin MS, Donigian JR, Cohen A, Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999;401(6749):188-93
   PubMed Web of Science ®Google Scholar
• Somoza JR, Skene RJ, Katz BA, Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 2004;12(7):1325-34
   PubMed Web of Science ®Google Scholar
• Vannini A, Volpari C, Filocamo G, Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci USA 2004;101(42):15064-9
   PubMed Web of Science ®Google Scholar
• Bottomley MJ, Lo Surdo P, Di Giovine P, Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J Biol Chem 2008;M803514200
   Google Scholar
• Ficner R. Novel structural insights into class I and II histone deacetylases. Curr Top Med Chem 2009;9(3):235-40
   PubMed Web of Science ®Google Scholar
• Ropero S, Fraga MF, Ballestar E, A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet 2006;38(5):566-9
   PubMed Web of Science ®Google Scholar
• Sjoblom T, Jones S, Wood LD, The consensus coding sequences of human breast and colorectal cancers. Science 2006;314(5797):268-74
   PubMed Web of Science ®Google Scholar
• Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 2009;8(6):1409-20
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128(4):683-92
   PubMed Web of Science ®Google Scholar
• Nakagawa M, Oda Y, Eguchi T, Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 2007;18(4):769-74
   PubMed Web of Science ®Google Scholar
• Zhang Z, Yamashita H, Toyama T, Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Res Treat 2005;94(1):11-6
   PubMed Web of Science ®Google Scholar
• Chang H-H, Chiang C-P, Hung H-C, Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. Oral Oncol 2009;45(7):610-14
   PubMed Web of Science ®Google Scholar
• Gloghini A, Buglio D, Khaskhely NM, Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. Br J Haematol 2009;147(4):515-25
   PubMed Web of Science ®Google Scholar
• Oehme I, Deubzer HE, Lodrini M, Targeting of HDAC8 and investigational inhibitors in neuroblastoma. Expert Opin Investig Drugs 2009;18(11):1605-17
   PubMed Web of Science ®Google Scholar
• Lin RJ, Sternsdorf T, Tini M, Evans RM. Transcriptional regulation in acute promyelocytic leukemia. Oncogene 2001;20(49):7204-15
   PubMed Web of Science ®Google Scholar
• Ayton PM, Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 2001;20(40):5695-707
   PubMed Web of Science ®Google Scholar
• Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007;25(1):84-90
   PubMed Web of Science ®Google Scholar
• Wang H, Dymock BW. New patented histone deacetylase inhibitors. Expert Opin Ther Pat 2009;19(12):1727-57
   PubMed Web of Science ®Google Scholar
• Schemies J, Sippl W, Jung M. Histone deacetylase inhibitors that target tubulin. Cancer Lett 2009;280(2):222-32
   PubMed Web of Science ®Google Scholar
• Varghese S, Senanayake T, Murray-Stewart T, Polyaminohydroxamic acids and polyaminobenzamides as isoform selective histone deacetylase inhibitors. J Med Chem 2008;51(8):2447-56
   PubMed Web of Science ®Google Scholar
• Marson C. Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer. Anti-cancer agents in medicinal chemistry 2009;9(6):661-92
   PubMed Web of Science ®Google Scholar
• Butler KV, Kozikowski AP. Chemical origins of isoform selectivity in histone deacetylase inhibitors. Curr Pharm Des 2008;14(6):505-28
   PubMed Web of Science ®Google Scholar
• Balasubramanian S, Verner E, Buggy JJ. Isoform-specific histone deacetylase inhibitors: the next step? Cancer Lett 2009;280(2):211-21
   PubMed Web of Science ®Google Scholar
• Mahboobi S, Dove S, Sellmer A, Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases. J Med Chem 2009;52(8):2265-79
   PubMed Web of Science ®Google Scholar
• Ruefli AA, Ausserlechner MJ, Bernhard D, The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 2001;98(19):10833-8
   PubMed Web of Science ®Google Scholar
• Ungerstedt JS, Sowa Y, Xu WS, Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005;102(3):673-8
   PubMed Web of Science ®Google Scholar
• Eot-Houllier G, Fulcrand G, Magnaghi-Jaulin L, Jaulin C. Histone deacetylase inhibitors and genomic instability. Cancer Lett 2009;274(2):169-76
   PubMed Web of Science ®Google Scholar
• Butler LM, Zhou X, Xu WS, The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 2002;99(18):11700-5
   PubMed Web of Science ®Google Scholar
• Gaymes TJ, Padua RA, Pla M, Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis? Mol Cancer Res 2006;4(8):563-73
   PubMed Web of Science ®Google Scholar
• Adimoolam S, Sirisawad M, Chen J, HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci USA 2007;104(49):19482-7
   PubMed Web of Science ®Google Scholar
• Munshi A, Kurland JF, Nishikawa T, Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 2005;11(13):4912-22
   PubMed Web of Science ®Google Scholar
• Frew AJ, Johnstone RW, Bolden JE. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 2009;280(2):125-33
   PubMed Web of Science ®Google Scholar
• Chen CS, Wang YC, Yang HC, Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Res 2007;67(11):5318-27
   PubMed Web of Science ®Google Scholar
• Fernandez-Capetillo O, Nussenzweig A. Linking histone deacetylation with the repair of DNA breaks. Proc Natl Acad Sci USA 2004;101(6):1427-8
   PubMed Web of Science ®Google Scholar
• Munshi A, Tanaka T, Hobbs ML, Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther 2006;5(8):1967-74
   PubMed Web of Science ®Google Scholar
• Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Nat Acad Sci USA 2000;97(18):10014-19
   PubMed Web of Science ®Google Scholar
• Gui CY, Ngo L, Xu WS, Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. ProcNatl Acad Sci USA 2004;101(5):1241-6
   PubMed Web of Science ®Google Scholar
• Rascle A, Johnston JA, Amati B. Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5. Mol Cell Biol 2003;23(12):4162-73
   PubMed Web of Science ®Google Scholar
• Wang LG, Ossowski L, Ferrari AC. Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line. Oncogene 2004;23(30):5175-84
   PubMed Web of Science ®Google Scholar
• Lee E-M, Shin S, Cha H, Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells. Intl J Mol Med 2009;24(1):45-50
   PubMed Web of Science ®Google Scholar
• Wilson AJ, Chueh AC, Togel L, Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction. Cancer Res 2010;70(2):609-20
   PubMed Web of Science ®Google Scholar
• Rosato RR, Grant S. Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets 2005;9(4):809-24
   PubMed Web of Science ®Google Scholar
• Zhao Y, Tan J, Zhuang L, Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci USA 2005;102(44):16090-5
   PubMed Web of Science ®Google Scholar
• Burgess A, Ruefli A, Beamish H, Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 2004;23(40):6693-701
   PubMed Web of Science ®Google Scholar
• Nakata S, Yoshida T, Horinaka M, Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 2004;23(37):6261-71
   PubMed Web of Science ®Google Scholar
• Insinga A, Monestiroli S, Ronzoni S, Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005;11(1):71-6
   PubMed Web of Science ®Google Scholar
• Xu W, Ngo L, Perez G, Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci USA 2006;103(42):15540-5
   PubMed Web of Science ®Google Scholar
• Jiang X, Wang X. Cytochrome C-mediated apoptosis. Annu Rev Biochem 2004;73:87-106
   PubMed Web of Science ®Google Scholar
• Coffey DC, Kutko MC, Glick RD, The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res 2001;61(9):3591-4
   PubMed Web of Science ®Google Scholar
• Borbone E, Berlingieri MT, De Bellis F, Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. Oncogene 2010;29(1):105-16
   PubMed Web of Science ®Google Scholar
• Rosato RR, Maggio SC, Almenara JA, The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Mol Pharmacol 2006;69(1):216-25
   PubMed Web of Science ®Google Scholar
• Zhang XD, Gillespie SK, Borrow JM, Hersey P. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol Cancer Ther 2004;3(4):425-35
   PubMed Web of Science ®Google Scholar
• Shao Y, Gao Z, Marks PA, Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 2004;101(52):18030-5
   PubMed Web of Science ®Google Scholar
• Xu WS, Perez G, Ngo L, Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects. Cancer Res 2005;65(17):7832-9
   PubMed Web of Science ®Google Scholar
• Cimini D, Mattiuzzo M, Torosantucci L, Degrassi F. Histone hyperacetylation in mitosis prevents sister chromatid separation and produces chromosome segregation defects. Mol Biol Cell 2003;14(9):3821-33
   PubMed Web of Science ®Google Scholar
• Taddei A, Maison C, Roche D, Almouzni G. Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases. Nat Cell Biol 2001;3(2):114-20
   PubMed Web of Science ®Google Scholar
• Dowling M, Voong KR, Kim M, Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents. Cancer Biol Ther 2005;4(2):197-206
   PubMed Web of Science ®Google Scholar
• Robbins AR, Jablonski SA, Yen TJ, Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin. Cell Cycle 2005;4(5):717-26
   PubMed Web of Science ®Google Scholar
• Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 2003;63(13):3637-45
   PubMed Web of Science ®Google Scholar
• Lillig CH, Holmgren A. Thioredoxin and related molecules – from biology to health and disease. Antioxid Redox Signal 2007;9(1):25-47
   PubMed Web of Science ®Google Scholar
• Marks PA. Thioredoxin in cancer: role of histone deacetylase inhibitors. Semin Cancer Biol 2006;16(6):436-43
   PubMed Web of Science ®Google Scholar
• Nishiyama A, Matsui M, Iwata S, Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem 1999;274(31):21645-50
   PubMed Web of Science ®Google Scholar
• Tan J, Zhuang L, Jiang X, Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity. J Biol Chem 2006;281(15):10508-15
   PubMed Web of Science ®Google Scholar
• Zhang YY, Gilquin BB, Khochbin SS, Matthias PP. Two catalytic domains are required for protein deacetylation. J Biol Chem 2006;281(5):2401-4
   PubMed Web of Science ®Google Scholar
• Bali P, Pranpat M, Bradner J, Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. JBiol Chem 2005;280(29):26729-34
   PubMed Web of Science ®Google Scholar
• Westendorf JJ, Zaidi SK, Cascino JE, Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol 2002;22(22):7982-92
   PubMed Web of Science ®Google Scholar
• Chen CS, Weng SC, Tseng PH, Lin HP. Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem 2005;280(46):38879-87
   PubMed Web of Science ®Google Scholar
• Solit DB, Rosen N. Hsp90: a novel target for cancer therapy. Curr Top Med Chem 2006;6(11):1205-14
   PubMed Web of Science ®Google Scholar
• Ellis L, Hammers H, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 2009;280(2):145-53
   PubMed Web of Science ®Google Scholar
• Liang D, Kong X, Sang N. Effects of histone deacetylase inhibitors on HIF-1. Cell Cycle 2006;5(21):2430-5
   PubMed Web of Science ®Google Scholar
• Kong X, Lin Z, Liang D, Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1 alpha. Mol Cell Biol 2006;26(6):2019-28
   PubMed Web of Science ®Google Scholar
• Qian DZ, Kachhap SK, Collis SJ, Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res 2006;66(17):8814-21
   PubMed Web of Science ®Google Scholar
• Kano Y, Akutsu M, Tsunoda S, Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines. Invest New Drugs 2007;25(1):31-40
   PubMed Web of Science ®Google Scholar
• Wardell SE, Ilkayeva OR, Wieman HL, Glucose metabolism as a target of histone deacetylase inhibitors. Mol Endocrinol 2009;23(3):388-401
   PubMed Web of Science ®Google Scholar
• Richon VM, Garcia-Vargas J, Hardwick JS. Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett 2009;280(2):201-10
   PubMed Web of Science ®Google Scholar
• Shiozawa K, Nakanishi T, Tan M, Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. Clin Cancer Res 2009;15(5):1698-707
   PubMed Web of Science ®Google Scholar
• Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 2009;280(2):233-41
   PubMed Web of Science ®Google Scholar
• Bots M, Johnstone RW. Rational combinations using HDAC inhibitors. Clin Cancer Res 2009;15(12):3970-7
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Bates SE. Epigenetic modifiers: basic understanding and clinical development. Clin Cancer Res 2009;15(12):3918-26
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Turner M, Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009;27(32):5410-17
   PubMed Web of Science ®Google Scholar
• Ma X, Ezzeldin HH, Diasio RB. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 2009;69(14):1911-34
   PubMed Web of Science ®Google Scholar
• Nolan L, Johnson PW, Ganesan A, Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential? Br J Cancer 2008;99(5):689-94
   PubMed Web of Science ®Google Scholar
• Jennifer LB, Yongyao X, Susanne JS, Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 2007;109(3):1123-30
   PubMed Web of Science ®Google Scholar
• Adcock IM. HDAC inhibitors as anti-inflammatory agents. Br J Pharmacol 2007;150(7):829-31
   PubMed Web of Science ®Google Scholar
• Villagra A, Sotomayor EM, Seto E. Histone deacetylases and the immunological network: implications in cancer and inflammation. Oncogene 2009;29(2):157-73
   PubMed Web of Science ®Google Scholar
• Andrews KT, Tran TN, Wheatley NC, Fairlie DP. Targeting histone deacetylase inhibitors for anti-malarial therapy. Curr Top Med Chem 2009;9(3):292-308
   PubMed Web of Science ®Google Scholar
• Kazantsev AG, Thompson LM. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev 2008;7(10):854-68
   Google Scholar
• Antonello M, Rotili D, Valente S, Kazantsev AG. Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise. Curr Pharm Des 2009;15(34):3940-57
   PubMed Web of Science ®Google Scholar
• Hockly E, Richon VM, Woodman B, Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 2003;100(4):2041-6
   PubMed Web of Science ®Google Scholar
• Cao H, Jung M, Stamatoyannopoulos G. Hydroxamide derivatives of short-chain fatty acid have erythropoietic activity and induce [gamma] gene expression in vivo. Exp Hematol 2005;33(12):1443-9
   PubMed Web of Science ®Google Scholar
• Lin HS, Hu CY, Chan HY, Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol 2007;150(7):862-72
   PubMed Web of Science ®Google Scholar
• Romagnani P, Lasagni L, Mazzinghi B, Pharmacological modulation of stem cell function. Curr Med Chem 2007;14(10):1129-39
   PubMed Web of Science ®Google Scholar
• Lee S, Park JR, Seo MS, Histone deacetylase inhibitors decrease proliferation potential and multilineage differentiation capability of human mesenchymal stem cells. Cell Prolif 2009;42(6):711-20
   PubMed Web of Science ®Google Scholar
• Butt MU, Sailhamer EA, Li Y, Pharmacologic resuscitation: cell protective mechanisms of histone deacetylase inhibition in lethal hemorrhagic shock. J Surg Res 2009;156(2):290-6
   PubMed Web of Science ®Google Scholar
• Botrugno OA, Santoro F, Minucci S. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. Cancer Lett 2009;280(2):134-44
   PubMed Web of Science ®Google Scholar
• Kelly WK, Marks PA. Drug insight: histone deacetylase inhibitors – development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2005;2(3):150-7
   PubMedGoogle Scholar
• Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Invest Drugs 2007;16(7):1111-20
   PubMed Web of Science ®Google Scholar
• Giles F, Fischer T, Cortes J, A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006;12(15):4628-35
   PubMed Web of Science ®Google Scholar
• Stimson L, La Thangue NB. Biomarkers for predicting clinical responses to HDAC inhibitors. Cancer Lett 2009;280(2):177-83
   PubMed Web of Science ®Google Scholar
• Fantin VR, Richon VM. Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. Clin Cancer Res 2007;13(24):7237-42
   PubMed Web of Science ®Google Scholar
• Powis G, Mustacich D, Coon A. The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med 2000;29(3-4):312-22
   PubMed Web of Science ®Google Scholar
• Chung YM, Yoo YD, Park JK, Increased expression of peroxiredoxin II confers resistance to cisplatin. Anticancer Res 2001;21(2A):1129-33
   PubMed Web of Science ®Google Scholar
• Kim SN, Kim NH, Lee W, Histone deacetylase inhibitor induction of P-glycoprotein transcription requires both histone deacetylase 1 dissociation and recruitment of CAAT/enhancer binding protein beta and pCAF to the promoter region. Mol Cancer Res 2009;7(5):735-44
   PubMed Web of Science ®Google Scholar
• Kelly WK, O'Connor OA, Krug LM, Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23(17):3923-31
   PubMed Web of Science ®Google Scholar
• Fujiwara Y, Yamamoto N, Yamada Y, Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. Cancer Sci 2009;100(9):1728-34
   PubMed Web of Science ®Google Scholar
• Modesitt SC, Sill M, Hoffman JS, Bender DP. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2008;109(2):182-6
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Van Cutsem E, Dumez H, Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs 2008;26(5):483-8
   PubMed Web of Science ®Google Scholar
• Blumenschein GR Jr, Kies MS, Papadimitrakopoulou VA, Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs 2008;26(1):81-7
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Parise RA, Ramanathan RK, Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 2007;13(12):3605-10
   PubMed Web of Science ®Google Scholar
• Luu TH, Morgan RJ, Leong L, A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res 2008;14(21):7138-42
   PubMed Web of Science ®Google Scholar
• Woyach JA, Kloos RT, Ringel MD, Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab 2009;94(1):164-70
   PubMed Web of Science ®Google Scholar
• Galanis E, Jaeckle KA, Maurer MJ, Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 2009;27(12):2052-8
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kato H, Kobayashi Y, Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Sci 2010;101(1):196-200
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Heaney ML, Schwartz L, Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006;24(1):166-73
   PubMed Web of Science ®Google Scholar
• Crump M, Coiffier B, Jacobsen ED, Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 2008;19(5):964-9
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Yang H, Bueso-Ramos C, Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008;111(3):1060-6
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Belani CP, Ruel C, Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol 2009;4(1):97-101
   PubMed Web of Science ®Google Scholar
• Steele NL, Plumb JA, Vidal L, A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 2008;14(3):804-10
   PubMed Web of Science ®Google Scholar
• Zain JM, Foss F, Kelly WK, Final results of a phase I study of oral belinostat (PXD101) in patients with lymphoma. (Meeting Abstracts). J Clin Oncol 2009;27(15S):8580
   Google Scholar
• Golay J, Cuppini L, Leoni F, The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia 2007;21(9):1892-900
   PubMed Web of Science ®Google Scholar
• Evens AM, Weiyun A, Balasubramanian S, Phase I analysis of the safety and pharmacodynamics of the broad spectrum histone deacetylase inhibitor (HDACi) PCI-24781 in relapsed and refractory lymphoma. Blood (ASH Annual Meeting) Abstract, Nov 2009, Am Society Hematol 2009;114:2726
   Google Scholar
• Arts J, King P, Marien A, JNJ-26481585, a novel ‘second-generation’ oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin Cancer Res 2009;15(22):6841-51
   PubMed Web of Science ®Google Scholar
• Novotny-Diermayr V, Sangthongpitag K, Hu CY, SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther 2010;9(3):642-52
   PubMed Web of Science ®Google Scholar
• Schrump DS, Fischette MR, Nguyen DM, Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin Cancer Res 2008;14(1):188-98
   PubMed Web of Science ®Google Scholar
• Shah MH, Binkley P, Chan K, Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2006;12(13):3997-4003
   PubMed Web of Science ®Google Scholar
• Fouladi M, Furman WL, Chin T, Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report. J Clin Oncol 2006;24(22):3678-85
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye AR, Wright JJ, Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 2006;12(12):3762-73
   PubMed Web of Science ®Google Scholar
• Reid T, Weeks A, Vakil M, Dose escalation study of pivanex (a histone deacetylase inhibitor) in combination with docetaxel for advanced non-small cell lung cancer. (Meeting Abstracts). J Clin Oncol 2004;22(14 Suppl):7279
   Google Scholar
• Carducci MA, Gilbert J, Bowling MK, A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res 2001;7(10):3047-55
   PubMed Web of Science ®Google Scholar
• Gilbert J, Baker SD, Bowling MK, A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 2001;7(8):2292-300
   PubMed Web of Science ®Google Scholar
• Phuphanich S, Baker SD, Grossman SA, Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. Neuro Oncol 2005;7(2):177-82
   PubMed Web of Science ®Google Scholar
• Camacho LH, Olson J, Tong WP, Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest New Drugs 2007;25(2):131-8
   PubMed Web of Science ®Google Scholar
• Kummar S, Gutierrez M, Gardner ER, Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res 2007;13(18 Pt 1):5411-17
   PubMed Web of Science ®Google Scholar
• Atmaca A, Al-Batran SE, Maurer A, Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 2007;97(2):177-82
   PubMed Web of Science ®Google Scholar
• Gore L, Rothenberg ML, O'Bryant CL, A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res 2008;14(14):4517-25
   PubMed Web of Science ®Google Scholar
• Siu LL, Pili R, Duran I, Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 2008;26(12):1940-7
   PubMed Web of Science ®Google Scholar